Cargando…

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance

In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with hepatocellular carcinoma (HCC). Following the positive results of the IMbrave150 trial, the combination of atezolizumab (an anti-PD-L1 antibody) and bevacizumab (an anti-VEGF antibody) became the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelizzaro, Filippo, Farinati, Fabio, Trevisani, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135644/ https://www.ncbi.nlm.nih.gov/pubmed/37189643 http://dx.doi.org/10.3390/biomedicines11041020

Ejemplares similares

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting
por: Plaz Torres, Maria Corina, et al.
Publicado: (2021)

Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies
por: Pinto, Elisa, et al.
Publicado: (2023)

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
por: De Lorenzo, Stefania, et al.
Publicado: (2022)

Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
por: Ji, Jun Ho, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
por: Federico, Piera, et al.
Publicado: (2020)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC
por: Marzi, Luca, et al.
Publicado: (2022)

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
por: Giannini, Edoardo G., et al.
Publicado: (2019)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
por: Dai, Xinlun, et al.
Publicado: (2020)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
por: van Doorn, Diederick J., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy for hepatocellular carcinoma
por: Ramai, Daryl, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2018)

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma
por: Guarino, Maria, et al.
Publicado: (2022)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
por: Ang, Celina, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
por: Guardascione, Michela, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Longo, Vito, et al.
Publicado: (2019)

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Dyhl-Polk, Anne, et al.
Publicado: (2021)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
por: Hung, Hao-Chien, et al.
Publicado: (2021)

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Park, Jong Chul, et al.
Publicado: (2022)

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
por: Hilmi, Marc, et al.
Publicado: (2019)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Masson, Claire, et al.
Publicado: (2023)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2afd9tr0qvodd8hnvoebsffr09